Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
19 February 2015 |
Main ID: |
NCT00167973 |
Date of registration:
|
11/09/2005 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
|
Scientific title:
|
A Prospective Registry of European Hemophilia B Patients Receiving BeneFIX®(Nonacog Alfa, Recombinant Human Factor IX) for Usual Use |
Date of first enrolment:
|
January 2002 |
Target sample size:
|
218 |
Recruitment status: |
Completed |
URL:
|
http://clinicaltrials.gov/show/NCT00167973 |
Study type:
|
Observational |
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
Phase:
|
|
|
Countries of recruitment
|
Austria
|
Belgium
|
France
|
Germany
|
Italy
|
Netherlands
|
Portugal
|
Spain
|
Sweden
|
United Kingdom
| | | | | | |
Contacts
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For UK, ukmedinfo@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Netherlands, trials-NL@wyeth.com |
|
Name:
|
Trial mANAGER |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Germany, MedInfoDEU@wyeth.com |
|
Name:
|
Medical Monitor |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Wyeth is now a wholly owned subsidiary of Pfizer |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Sweden, MedInfoNord@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Italy, descresg@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Austria, WPVIMED@wyeth.com |
|
Name:
|
Trial Manager |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
For Belgium, trials-BEL@wyeth.com |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with Hemophilia B scheduled to begin treatment with BeneFIX are eligible for
Registry enrollment
Exclusion Criteria:
Age minimum:
N/A
Age maximum:
N/A
Gender:
Both
|
Health Condition(s) or Problem(s) studied
|
Hemophilia B
|
Primary Outcome(s)
|
Observation for safety
[Time Frame: Study Duration]
|
Secondary ID(s)
|
3090A-101039
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|